Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Lopez

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
European Heart Journal. Cardiovascular Imaging|June 9, 2021
Aortic flow dynamics and stiffness in Loeys-Dietz syndrome patients: a comparison with healthy volunteers and Marfan syndrome patientsAroa Ruiz-Muñoz, Andrea Guala, Jose Rodriguez-Palomares, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2019
Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate CancerWolfgang P Fendler, Manuel Weber, Amir Iravani, et al.
The Lancet. Oncology|February 8, 2022
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trialMatthew R Smith, Howard I Scher, Shahneen Sandhu, et al.
The New England Journal of Medicine|February 9, 2018
Apalutamide Treatment and Metastasis-free Survival in Prostate CancerMatthew R Smith, Fred Saad, Simon Chowdhury, et al.
European Urology Oncology|May 6, 2025
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE TrialKim N Chi, Elena Castro, Gert Attard, et al.
The Lancet. Oncology|October 4, 2019
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 studyNeeraj Agarwal, Kelly McQuarrie, Anders Bjartell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2023
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate CancerKim N Chi, Dana Rathkopf, Matthew R Smith, et al.
Journal of Managed Care & Specialty Pharmacy|July 5, 2023
Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defectsMatthew R Smith, Shahneen Sandhu, Daniel J George, et al.
Future Oncology (London, England)|March 31, 2025
A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancerKim N Chi, Dana Rathkopf, Matthew R Smith, et al.
European Heart Journal|May 20, 2025
Myopericardial complications following COVID-19 disease and vaccination: a clinical consensus statement of the European Society of Cardiology Working Group on Myocardial and Pericardial DiseasesMassimo Imazio, Cristina Basso, Antonio Brucato, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
European Heart Journal. Cardiovascular Imaging|June 9, 2021
Aortic flow dynamics and stiffness in Loeys-Dietz syndrome patients: a comparison with healthy volunteers and Marfan syndrome patientsAroa Ruiz-Muñoz, Andrea Guala, Jose Rodriguez-Palomares, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2019
Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate CancerWolfgang P Fendler, Manuel Weber, Amir Iravani, et al.
The Lancet. Oncology|February 8, 2022
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trialMatthew R Smith, Howard I Scher, Shahneen Sandhu, et al.
The New England Journal of Medicine|February 9, 2018
Apalutamide Treatment and Metastasis-free Survival in Prostate CancerMatthew R Smith, Fred Saad, Simon Chowdhury, et al.
European Urology Oncology|May 6, 2025
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE TrialKim N Chi, Elena Castro, Gert Attard, et al.
The Lancet. Oncology|October 4, 2019
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 studyNeeraj Agarwal, Kelly McQuarrie, Anders Bjartell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2023
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate CancerKim N Chi, Dana Rathkopf, Matthew R Smith, et al.
Journal of Managed Care & Specialty Pharmacy|July 5, 2023
Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defectsMatthew R Smith, Shahneen Sandhu, Daniel J George, et al.
Future Oncology (London, England)|March 31, 2025
A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancerKim N Chi, Dana Rathkopf, Matthew R Smith, et al.
European Heart Journal|May 20, 2025
Myopericardial complications following COVID-19 disease and vaccination: a clinical consensus statement of the European Society of Cardiology Working Group on Myocardial and Pericardial DiseasesMassimo Imazio, Cristina Basso, Antonio Brucato, et al.
Pageof 8